Microbleed prevalence and burden in anticoagulant-associated intracerebral bleed.
Citation: Annals of Clinical & Translational Neurology. 6(8):1546-1551, 2019 08.PMID: 31402613Institution: MedStar Washington Hospital CenterDepartment: Surgical Critical CareForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Anticoagulants/tu [Therapeutic Use] | *Cerebral Hemorrhage/dt [Drug Therapy] | *Vitamin K/tu [Therapeutic Use] | Administration, Oral | Aged | Aged, 80 and over | Cohort Studies | Female | Humans | Male | Middle Aged | Prevalence | Retrospective Studies | Stroke | Vitamin K/ai [Antagonists & Inhibitors]Year: 2019ISSN:- 2328-9503
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 31402613 | Available | 31402613 |
Copyright (c) 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Prior studies suggest an association between Vitamin K antagonists (VKA) and cerebral microbleeds (CMBs); less is known about nonvitamin K oral anticoagulants (NOACs). In this observational study we describe CMB profiles in a multicenter cohort of 89 anticoagulation-related intracerebral hemorrhage (ICH) patients. CMB prevalence was 51% (52% in VKA-ICH, 48% in NOAC-ICH). NOAC-ICH patients had lower median CMB count [2(IQR:1-3) vs. 7(4-11); P < 0.001]; >=5 CMBs were less prevalent in NOAC-ICH (4% vs. 31%, P = 0.006). This inverse association between NOAC exposure and high CMB count persisted in multivariable logistic regression models adjusting for potential confounders (OR 0.10, 95%CI: 0.01-0.83; P = 0.034).
English